- Pfizer promotes 'underappreciated' R&D pipeline
- With $36bn from Teva, what should Allergan buy next?
- ProTide man Chris McGuigan hopes to make Nucana the next Gilead
- Tangled in the web of mass generic consolidation? Let Scrip explain
COMMENT Other Informa Comment
- Profile: Fred Hassan, pharma titan, gooseberry picker and secret geography geek
- PROFILE: AstraZeneca's Mene Pangalos on yin and yang, not believing your own press, and his part in Soriot's vision